Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or D(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Overview
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or D(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or D(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or D(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Companies Involved in Therapeutics Development
AbbVie Inc
AstraZeneca Plc
BeiGene Ltd
Clovis Oncology Inc
Convalife
GlaxoSmithKline Plc
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc
Ildong Pharmaceutical Co Ltd
Jeil Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Oncology Venture U.S. Inc
Shanghai Acebright Pharmaceuticals Group Co Ltd
Shanghai De Novo Pharmatech Co Ltd
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or D(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Drug Profiles
2X-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABT-767 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-0108 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cediranib maleate + olaparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceralasertib + olaparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVL-218 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HWH-340 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IDX-1197 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JPI-547 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
niraparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olaparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pamiparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rucaparib camsylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-10914 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-3162 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target NO and PARP 1, 2, 3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SOMCL-9112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veliparib ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YHP-743 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or D(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Dormant Products
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or D(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Discontinued Products
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or D(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Product Development Milestones
Featured News & Press Releases
Appendix



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Products under Development by Companies, H1 2020 (Contd..8), H1 2020
Products under Development by Companies, H1 2020 (Contd..9), H1 2020
Products under Development by Companies, H1 2020 (Contd..10), H1 2020
Products under Development by Companies, H1 2020 (Contd..11), H1 2020
Products under Development by Companies, H1 2020 (Contd..12), H1 2020
Products under Development by Companies, H1 2020 (Contd..13), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AbbVie Inc, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by BeiGene Ltd, H1 2020
Pipeline by Clovis Oncology Inc, H1 2020
Pipeline by Convalife, H1 2020
Pipeline by GlaxoSmithKline Plc, H1 2020
Pipeline by Hubei Bio-Pharmaceutical Industrial Technological Institute Inc, H1 2020
Pipeline by Ildong Pharmaceutical Co Ltd, H1 2020
Pipeline by Jeil Pharmaceutical Co Ltd, H1 2020
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
Pipeline by Oncology Venture U.S. Inc, H1 2020
Pipeline by Shanghai Acebright Pharmaceuticals Group Co Ltd, H1 2020
Pipeline by Shanghai De Novo Pharmatech Co Ltd, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020